ReviewFrontiers in cellular neuroscience2019
The Endocannabinoid System as a Window Into Microglial Biology and Its Relationship to Autism.
Review in Frontiers in cellular neuroscience, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 42 citations in OpenAlex.
- Anandamide blocks spatial memory reconsolidation in male rats through a CB1 receptor dependent mechanism.Psychopharmacology · 2026Article
- Beyond Infections: Exploring Immune-Mediated Pathways Linking Cannabis and Emerging Environmental Contaminants to Neurodevelopmental Outcomes.Advances in experimental medicine and biology · 2025Review
- Acute cannabis intoxication among the paediatric population.Frontiers in toxicology · 2025Review
- The effect of cannabinoid type Ⅱ receptor on the excitability of substantia nigra dopaminergic neurons.Frontiers in pharmacology · 2025Article
- Anandamide and WIN 55212-2 Afford Protection in Rat Brain Mitochondria in a Toxic Model Induced by 3-Nitropropionic Acid: an In Vitro Study.Molecular neurobiology · 2024Article
- Interplay Between Astroglial Endocannabinoid System and the Cognitive Dysfunction in Alzheimer's Disease.Physiological research · 2023Review
- Microglial Cannabinoid CBInternational journal of molecular sciences · 2023Review
- Individually tailored dosage regimen of full-spectrum Cannabis extracts for autistic core and comorbid symptoms: a real-life report of multi-symptomatic benefits.Frontiers in psychiatry · 2023Article
- Review
- Microglial Endocannabinoid Signalling in AD.Cells · 2022Review
- Clinical Data on Canabinoids: Translational Research in the Treatment of Autism Spectrum Disorders.Biomedicines · 2022Review
- Use of computational toxicology tools to predictCurrent research in toxicology · 2022Article
- Alterations of the endocannabinoid system and its therapeutic potential in autism spectrum disorder.Open biology · 2021Article
- Endocannabinoid System Unlocks the Puzzle of Autism TreatmentFrontiers in psychiatry · 2021Review
- Cannabidiol and Neurodevelopmental Disorders in Children.Frontiers in psychiatry · 2021Review
- The Dynamic Role of Microglia and the Endocannabinoid System in Neuroinflammation.Frontiers in pharmacology · 2021Review
- Microglia Specific Drug Targeting Using Natural Products for the Regulation of Redox Imbalance in Neurodegeneration.Frontiers in pharmacology · 2021Review
- Neurobiology of cannabinoid receptor signaling .Dialogues in clinical neuroscience · 2020Review
- Is Cannabidiol During Neurodevelopment a Promising Therapy for Schizophrenia and Autism Spectrum Disorders?Frontiers in pharmacology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Microglia are the resident, innate immune cells of the central nervous system (CNS) and are critical in managing CNS injuries and infections. Microglia also maintain CNS homeostasis by influencing neuronal development, viability, and function. However, aberrant microglial activity and phenotypes are associated with CNS pathology, including autism spectrum disorder (ASD). Thus, improving our knowledge of microglial regulation could provide insights into the maintenance of CNS homeostasis as well as the prevention and treatment of ASD. Control of microglial activity is in part overseen by small, lipid-derived molecules known as endogenous cannabinoids (endocannabinoids). Endocannabinoids are one component of the endocannabinoid system (ECS), which also includes the enzymes that metabolize these ligands, in addition to cannabinoid receptor 1 (CB
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.